Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Immunis
AddedFeb 17, 2024
UpdatedJun 18, 2026
Immunis

Immunis

Series A

Immunis: A private biotech firm innovating stem cell treatments for age and disease-related immunity decline.

HQ
Irvine, CA, US
Founded
2018
Overview
Compare
Fundraising
Employees
Website

Immunis, founded in Irvine, California, is a private biotechnology company focused on developing innovative stem cell treatments to combat age and disease-related immune decline. The company's core mission is to enhance the quality of life by reversing immune system deterioration through advanced biotechnological solutions. Immunis offers novel therapeutic products aimed at rejuvenating the immune system, targeting markets primarily concerned with aging populations and chronic disease management.

Notable figures affiliated with Immunis include Chairman Dr. Hans Keirstead, a recognized expert in stem cell research who has been invited to present at the Bio International Convention and received an honorary Ph.D. from the University of New Brunswick. The company has achieved significant milestones, including a partnership with Japanese drug company Toray to address sarcopenia. Immunis's pioneering work in stem cell therapy has positioned it as a key player in the biotech industry, making substantial strides in improving immune health and longevity.

Immunis - Similar Companies

ImStem Biotechnology logo

ImStem Biotechnology

imstem.com

ImmuneBridge logo

ImmuneBridge

immunebridge.com

Immunaeon logo

Immunaeon

immunaeon.com

Immusoft logo

Immusoft

immusoft.com

ImmunityBio logo

ImmunityBio

immunitybio.com

Inimmune logo

Inimmune

inimmune.com

HI-Bio logo

HI-Bio

hibio.com

ImmuneTarget logo

ImmuneTarget

Imunon logo

Imunon

imunon.com

Immunai logo

Immunai

Immunome logo

Immunome

ImmunoVec logo

ImmunoVec

immunovec.com

Thymmune Therapeutics logo

Thymmune Therapeutics

thymmune.com

INmune Bio logo

INmune Bio

inmunebio.com

ImmunGene logo

ImmunGene

Immunis - Quick Facts

Who are Immunis' competitors?

Companies similar to Immunis include ImStem Biotechnology, ImmuneBridge, Immunaeon and Immusoft.

When was Immunis founded?

Immunis was founded in 2018.

Where is Immunis' headquarters located?

Immunis' headquarters is located in Irvine, CA, US.

When was Immunis' last funding round?

Immunis' most recent funding round was for $10M (USD) in August 2022.

How much has Immunis raised to-date?

As of Aug 3, 2022, Immunis has raised a total of $10M (USD).

How many employees does Immunis have?

Immunis has 8 employees as of Feb 5, 2024.

Immunis - Classification

Ownership
  • Private
Technology
  • Biotech
Geographic Exposure
  • United States
Revenue
  • Licensing
  • Recurring
  • Software
Customer
  • Enterprise
Main Product
  • Stem Cell Therapies
Tags
  • Biotech
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541500Computer Systems Design and Related Services
  • 541000Professional, Scientific, and Technical Services
  • 541510Computer Systems Design and Related Services
  • 541511Custom Computer Programming Services
SIC
  • 7300Business Services
  • 7370Computer Programming, Data Processing, And Other Computer Related
  • 7371Computer Programming Services
Show 5 more industry codes
NAICS
  • 513200Software Publishers
  • 510000Information
  • 513000Publishing Industries
  • 513210Software Publishers
SIC
  • 7372Prepackaged Software